Although the specific therapies targeting visfatin and resistin have not yet been established, recent findings have found an anti-inflammatory factor called “adropin” and have been speculated as the antagonist to suppress the mRNA level of these two adipokines [212,213] which might become a potential therapeutic strategy to reduce obesity and obesity-related CVD in both males and females. This evidence concerns the gene RETN and obesity due to melanocortin 4 receptor deficiency.